Home » Research » Liv.52(tablet,syrup)

(Research papers based on Indications)

Viral Hepatitis

  1. Liv.52: Profile of an Herbal remedy
    B.L.Chauhan, Ph.D., M.D., and R.D.Kulkarni are associated with The Himalaya Drug Co., R&D Centre, Makali, Bangalore 562123, India. Drug News and Prospectives, November 1993.

    B.L. CHAUHAN and R.D. KULKARNI, M.D., R and D Centre, The Hiimalaya Drug Co., Bombay. Eur.J. Clin Pharmacot. (1991): 40, 189-191

    M. K. SARI(AR, M.B.,B.S., Medical Officer-in-charge, Burn & co., Durgapur-l, Burdwan. The Indian Practiotioner (1973): 8, 395.

  4. Evaluation of Efficacy and Safety of Liv.52 Tablet in Acute Alcoholic Hepatitis: An Open Clinical Study
    SV Dange*, Abhijit Nikam*, Mangesh Kamale*. Indian Journal of Clinical Practice, Vol. 22, No. 7, December 2011

  5. Meta-analysis of 50 Phase III clinical trials in evaluation of efficacy and safety of Liv.52 in infective hepatitis
    Kolhapure, S.A., M.D., Senior Medical Advisor, and Mitra, S.K., M.D., Executive Director,Research and Technical Service, R&D Center, The Himalaya Drug Company, Bengaluru, India, Medicine Update (2004): 12(2), 51-61.

  6. Efficacy of an indigenous compound preparation Liv.52 in acute viral hepatitis – A double-blind study
    Sama, S.K., Krishnamurthy, L., Ramachandran, K. and Krishnan Lal, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, Indian Journal of Medical Research (1976): 5, 738.

  7. New Drug Development using Korean Herbal Formulae: A model role study
    Jung-Hyo Cho, Jing-Hua Wang, Chang-Gue Son*
    *Liver-Immune Department of Daejeon Oriental Hospital of Daejeon University. 22-5 Daeheung-dong, Jung-gu, Daejeon, 301-724, South Korea
    The Journal of Korean Oriental Medicine. 2009. Vol.30. No.6. 96-102.

  8. Comparative hepatoprotective activity of Liv-52 and livomyn against carbon tetrachloride-induced hepatic injury in rats
    V.D. Sapakal, R.V. Ghadge, R.S. Adnaik, N.S. Naikwade, C.S. Magdum
    Department of Pharmacology, Appasaheb Birnale College of Pharmacy, Sangli, Maharashatra, India
    International Journal of Green Pharmacy. April-June 2008.

  9. Hepatoprotective activity of six polyherbal formulations in CCl4-induced liver toxicity in mice
    C Girish*, Bidhan Chandra Konera, S Jayanthib, K Ramachandra Raoc, B Rajeshc & Suresh Chandra Pradhan
    Department of Pharmacology, Biochemistrya, Pathologyb and Anatomyc, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, India, 605 006.
    Indian Journal of Experimental Biology. Vol. 47, April 2009, pp. 257-263.

  10. Liv.52 attenuate copper induced toxicity by inhibiting glutathione depletion and increased antioxidant enzyme activity in HepG2 cells
    Satyakumar Vidyashankar a,*, Pralhad Sadashiv Patki b
    a Department of Cell Biology and Biochemistry, Research and Development, The Himalaya Drug Company, Makali, Bengaluru 562 123, India.
    b Department of Medical Services and Clinical Trials, Research and Development, The Himalaya Drug Company, Makali, Bengaluru 562 162, India.
    Food and Chemical Toxicology 48 (2010) 1863–1868.

  11. Hepatoprotective activity of six polyherbal formulations in paracetamol induced liver toxicity in mice
    C. Girish, B.C. Koner*, S. Jayanthi**, K.R. Rao, B. Rajesh & S.C. Pradhan
    Departments of Pharmacology, *Biochemistry, **Pathology & Anatomy, Jawaharlal Institute of Postgraduate Medical Education & Research, Puducherry, India.
    The Indian Journal of Medical Research, 129, May 2009, pp 569-578.

    Department of Pharmacy, Annamalai University, Annamalai Nagar, Chidambaram, Tamil Nadu 608002, India.
    International Journal of Pharmacy and Pharmaceutical Sciences, Vol 4, Suppl 3, 2012.

  13. Liv.52 up-regulates cellular antioxidants and increase glucose uptake to circumvent oleic acid induced hepatic steatosis in HepG2 cells
    Satyakumar Vidyashankara,*, L.M. Sharath Kumarb, Vandana Barooaha, R. Sandeep Varmaa, Krishna S. Nandakumara, Pralhad Sadashiv Patkic
    a Cell Biology and Biochemistry, Research and Development, The Himalaya Drug Company, Makali, Bengaluru 562 123, India.
    b Phytochemistry, Research and Development, The Himalaya Drug Company, Makali, Bengaluru 562 123, India.
    c Medical Services and Clinical Trials, Research and Development, The Himalaya Drug Company, Makali, Bengaluru 562 123, India.
    Phytomedicine. 2012

  14. A Novel Herbal Formulation ‘‘LiverCare’’ Differentially Regulates Primary Rat Hepatocyte and Hepatocarcinoma Cell Proliferation In Vitro
    Satyakumar Vidyashankar1, Sandeep Varma R1, Mohammed Azeemudin2, Ashok Godavarthi1, Krishna S. Nandakumar1 and Pralhad Sadashiv Patki3
    Departments of 1Cell Biology and Biochemistry, 2Pharmacology and Toxicology, and 3Medical Services and Clinical Trials, Research and Development, The Himalaya Drug Company, Makali, Bengaluru, India.
    JOURNAL OF MEDICINAL FOOD. 14 (9) 2011, 1–9.

Alcoholic Liver Disease

  1. Effect of the hepatoprotective drug Liv.52 on liver damage
    M. Kalab, T. Krechler Internal Clinic of the Medical Faculty of the Charles University in Prague and The Military Faculty Hospital in Prague, The Journal of Czech Physicians (1997): (136), 24, 758-760.

  2. Effect of Liv.52, a herbal preparation, on absorption and metabolism of ethanol in humans
    Chauhan, B.L. and Kulkarni, R.D., R&D Centre, The Himalaya Drug Co., Bombay, Maharashtra, European Journal of Clinical Pharmacology (1991): 40, 189.

  3. Blood, urine ethanol and acetaldehyde levels from six different alcoholic beverages and effect of Liv.52
    Kulkarni, R.D. and Chauhan, B.L., R&D Centre, The Himalaya Drug Co., Bombay, Maharashtra, European Journal of Pharmacology (1990): (183), 5, 1865.

Pre-cirrhotic conditions and early cirrhosis

  1. The efficacy of Liv-52 on liver cirrhotic patients: A randomized, double-blind, placebo-controlled first approach
    H. Fallah Huseinia*, S.M. Alavianb, R. Heshmatc, M.R. Heydarid, K. Abolmaalie
    a Department of Pharmacology, Institute of Medicinal Plants, No. 97, Bozorgmehr St., Ghods St., Enghelab Ave., Tehran, Iran. b Baqiatallah University of Medical Sciences, Tehran Hepatitis Center, Tehran, Iran.
    c Department of Epidemiology and Biostatistics, Tehran University of Medical Sciences, Tehran, Iran.
    d Endocrinology & Metabolism Research Center, Tehran University of Medical Sciences, Tehran, Iran.
    e Baqiatallah University of Medical Sciences, Tehran, Iran Phytomedicine 12(2005) 619-624.

  2. Therapy of cirrhosis of liver and liver damage with indigenous drugs – Experimental and clinical studies
    Shantilal C. Sheth, Basil J. Northover, Tibrewala, N.S., Warerkar, U.R. and Karande, V.S. B.Y.L. Nair Hosptial and Topiwala National Medical College and the Christian Medical College and Hospital, Vellore, Tamil Nadu, Indian Journal of Paediatrics (1960): 27, 204.

Radiation and chemotherapy-induced liver damage

  1. Liv.52 in the Prevention of Hepatotoxicity in Patients Receiving Antitubercular Drugs: A Meta-analysis
    SV Dange Professor, Dept. of Pharmacology DY Patil Medical College, Hospital and Research Centre, Pune Indian Journal of Clinical Practice, Vol. 21, No. 2, July 2010

As an adjuvant with hepatotoxic drugs

  1. Effect of phytotherapy on prevention and elimination of hepatotoxic reactions in patients with pulmonary tuberculosis and carriers of hepatitis B virus markers
    Galitsky, L.A., Barnaulov, O.D., Zaretskii, B.V., Malkov, M.I., Konenkov, S.I., Gol’m, N.P., Tomakov, V.S., Ogarkov, P.I. and Batskov, S.S. Military Academy of Medicine, Human Brain Institute of the Russian Academy of Sciences, Saint-Petersburg, Russia, Problems of Tuberculosis, (1997): 4, 35.


  1. Use of hepatoprotective agents in hepatomegaly syndrome in children: An experience with Liv.52 Syrup
    Otilia Marginean, MD, PhD, Ioana Micle, MD, PhD, Maria Lesovici, MD, PhD, Pediatric Hospital "Louis Turcanu", Timisoara, Romania, Raluca Balean, MD, Budiu Ioana, MD, County Hospital Nr. 1, Timisoara, Romania, and Edited by: Kala Suhas Kulkarni, MD, MCPS Medical Advisor, R&D Center, The Himalaya Drug Company, Bengaluru, Karnataka, India, Medicine Update (2002): (10), 8, 57.

    Padmaja S Nikam*1, Shashikant V Nikam1 and Ajit Sontakke2 ; 1Department of Biochemistry, Belgaum Institute of Medical Sciences, Belgaum, Karnataka, India. 2Department of Biochemistry, KIMS, Karad, Maharashtra, India. Nikam P S et al. / Pharmacie Globale (IJCP) 2011, 10 (06)

  3. Role of Liv.52 in Non-Infectious Chronic Liver Disease
    Khalid Abdulla Al-Khazraji1, Ali Khalid2, Mohammed Kamal Hashim3, Mahmood Kamal Hashim4, Safia Khalid Abdulla5, Mohammed Khalid Abdulla6, Issam Hadi Khudhair7 & Wissam Khudhair Abbas8.
    1 MBChB, MD, CAMB, FRCP, FACP, Professor of Gastroenterology, College of Medicine, Baghdad University, Iraq
    2 MBChB, FICM, Baghdad Teaching Hospital, Iraq
    3 Department of Surgery, Baghdad Teaching Hospital, Iraq
    4 Department of Dermatology, Baghdad Teaching Hospital, Iraq
    5 College of Medicine, Al-Iraqia University, Iraq
    6 Medical student 4th grade, Baghdad Medical College, Iraq
    7 Medical student 6th grade, Pleven Medical University
    8 College of Medicine, Al-Mustansiriya University, Iraq
    Global Journal of Health Science Vol. 14, No. 7; 2022

  4. Hepatoprotective Effects of Liv.52 in Chronic Liver Disease Preclinical, Clinical, and Safety Evidence: A Review
    Chetan Kantharia 1, Munesh Kumar 2, Mukesh Kumar Jain 3, Lokendra Sharma 4, Lokesh Jain 5 and Anish Desai 6,*
    1 Department of Surgical Gastroenterology, Seth G S Medical College and K E M Hospital, Mumbai 400012, India
    2 Department of Medicine, RUHS-CMS and Attached Hospital, Jaipur 302033, India
    3 MG Medical College & Hospital, Jaipur 302022, India
    4 Department of Pharmacology, SMS Medical College, Jaipur 302004, India
    5 Department of Hepatology, Mahatma Gandhi Medical College, Jaipur 302022, India; drlokeshswm@gmail.com
    6 Department of Pharmaceutical Medicine, Maharashtra University of Health Sciences, Nashik 422004, India
    * Correspondence: dranishdesai@intellimed.org; Tel.: +91-982-012-6989